Condition
Plasma Cell Leukemia (PCL) clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Plasma Cell Leukemia (PCL) clinical trials that are recruiting, at sites in 2 countries (most in China (3), United Kingdom (1)). By phase: Phase 2 (2), Phase 3 (1), Early Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest Plasma Cell Leukemia (PCL) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| CM336 plus Isa-VR in newly diagnosed primary plasma cell leukemia | Phase 2 | Tianjin, Tianjin Municipality | Recruiting | Jun 17, 2026 |
| Personalising Myeloma Treatment Based on Initial Response and Fitness | Phase 3 | Bristol and 4 other locations | Recruiting | Jun 16, 2026 |
| IL-15–armored CAR-T for relapsed or refractory multiple myeloma and plasma cell leukemia | Phase 2 | Changchun, Jilin | Recruiting | Apr 3, 2026 |
| Metabolically armed BCMA CAR-T (Meta10-BCMA) for relapsed or refractory plasma cell neoplasms | Early Phase 1 | Hefei, Anhui | Recruiting | Jul 25, 2025 |
All recruiting trials (4)
-
CM336 plus Isa-VR in newly diagnosed primary plasma cell leukemia
A new combination therapy using CM336 with isatuximab, lenalidomide, and bortezomib is being tested in adults newly diagnosed with primary plasma cell leukemia to see if it can improve treatment responses and safety.
-
Personalising Myeloma Treatment Based on Initial Response and Fitness
This trial tests whether adjusting treatment after six months of the standard DRd therapy, based on a patient’s response and fitness, can improve outcomes for older, transplant-ineligible patients with myeloma.
-
IL-15–armored CAR-T for relapsed or refractory multiple myeloma and plasma cell leukemia
This trial will test IL-15–armored CAR-T cell therapy to see if it helps adults with relapsed or refractory multiple myeloma or plasma cell leukemia, including those with persistent or returning MRD.
-
Metabolically armed BCMA CAR-T (Meta10-BCMA) for relapsed or refractory plasma cell neoplasms
This treatment tries a metabolically modified BCMA-targeted CAR-T cell therapy for adults with relapsed or refractory multiple myeloma, plasma cell leukemia, or AL amyloidosis who have had at least three prior therapies.
Related topics
Quick answers
How many Plasma Cell Leukemia (PCL) clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (3 trials), United Kingdom (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 3: 1, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.